Skeletal deterioration induced by RANKL infusion: A model for high-turnover bone disease

Osteoporosis International

Volumn 19, Issue 5, 2008, Pages 625-635

  Yuan, Y Y ^a   Kostenuik, P J ^b   Ominsky, M S ^b   Morony, S ^b   Adamu, S ^b   Simionescu, D T ^a   Basalyga, D M ^a   Asuncion, F J ^b   Bateman, T A ^a  

^a AMRL   (United States)

^b AMGEN INC   (United States)

Author keywords

Bone; Diseases; Model; Osteoporosis; RANKL; Resorption

Indexed keywords

OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE 5B;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BLOOD SAMPLING; BONE ATROPHY; BONE DISEASE; BONE MINERAL; BONE MINERALIZATION; BONE STRUCTURE; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; FEMUR; MALE; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RAT; SKELETON; TIBIA; TRABECULAR BONE;

ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DISEASE MODELS, ANIMAL; MALE; OSTEOPOROSIS; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY;

EID: 43149095800     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0509-7     Document Type: Article

References (44)

1. Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. Jama 292:490-495
2. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588-1594
3. Blair JM, Zhou H, Seibel MJ et al (2006) Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3:41-49
4. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504-1508
5. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342
6. Suda T, Takahashi N, Udagawa N et al (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357
7. Zaidi M, Blair HC, Moonga BS et al (2003) Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 18:599-609
8. Fuller K, Wong B, Fox S et al (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188:997-1001
9. Eghbali-Fatourechi G, Khosla S, Sanyal A et al (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221-1230
10. Anderson DM, Maraskovsky E, Billingsley WL et al (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179
11. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
12. Yasuda H, Shima N, Nakagawa N et al (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
13. Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
14. Tsuda E, Goto M, Mochizuki S et al (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142
15. Nagai M, Sato N (1999) Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem Biophys Res Commun 257:719-723
16. Fazzalari NL, Kuliwaba JS, Atkins GJ et al (2001) The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res 16:1015-1027
17. Grimaud E, Soubigou L, Couillaud S et al (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163:2021-2031
18. Haynes DR, Crotti TN, Loric M et al (2001) Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 40:623-630
19. Kong YY, Feige U, Sarosi I et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309
20. Stolina M, Adamu S, Ominsky M et al (2005) RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 20:1756-1765
21. Giuliani N, Bataille R, Mancini C et al (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527-3533
22. Standal T, Seidel C, Hjertner O et al (2002) Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100:3002-3007
23. Michigami T, Ihara-Watanabe M, Yamazaki M et al (2001) Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61:1637-1644
24. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593
25. Fuller K, Gallagher AC, Chambers TJ (1991) Osteoclast resorption-stimulating activity is associated with the osteoblast cell surface and/or the extracellular matrix. Biochem Biophys Res Commun 181:67-73
26. Ikeda T, Kasai M, Utsuyama M et al (2001) Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 142:1419-1426
27. Suzuki J, Ikeda T, Kuroyama H et al (2004) Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun 314:1021-1027
28. Avbersek-Luznik I, Balon BP, Rus I et al (2005) Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 20:566-570
29. Geusens PP, Landewe RB, Garnero P et al (2006) The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 54:1772-1777
30. Morabito N, Gaudio A, Lasco A et al (2004) Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 19:722-727
31. Abrahamsen B, Hjelmborg JV, Kostenuik P et al (2005) Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone 36:727-735
32. Min H, Morony S, Sarosi I et al (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474
33. Broz JJ, Simske SJ, Greenberg AR et al (1993) Effects of rehydration state on the flexural properties of whole mouse long bones. J Biomech Eng 115:447-449
34. Ross AB, Bateman TA, Kostenuik PJ et al (2001) The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med 12:583-588
35. Parfitt AM, Drezner MK, Glorieux FH et al (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
36. Stilgren LS, Hegedus LM, Beck-Nielsen H et al (2003) Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif Tissue Int 73:210-216
37. Stilgren LS, Rettmer E, Eriksen EF et al (2004) Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 35:256-265
38. Heaney RP (2003) Is the paradigm shifting? Bone 33:457-465
39. Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97-104
40. Bucay N, Sarosi I, Dunstan CR et al (1998) osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268
41. Abdallah BM, Stilgren LS, Nissen N et al (2005) Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif Tissue Int 76:90-97
42. Beck TJ, Miller PD, Lewiecki EM (2006) Denosumab improves the structural geometry of the proximal femur in postmenopausal women with low bone mass. J Bone Min Res 21:S71 (Abstract)
43. McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831
44. Body JJ, Facon T, Coleman RE et al (2006) A study of the biological receptor activator of nuclear factor-{kappa}B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221-1228